Skip to main content
SpringerLink
Log in

Cariprazine: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 03 February 2016

Abstract

Cariprazine (Vraylar™) is an oral atypical antipsychotic originated by Gedeon Richter. It is a potent dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. Cariprazine also has partial agonist activity at serotonin 5-HT1A receptors. In September 2015, cariprazine received its first global approval in the USA for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. It is also in development in a variety of countries for the treatment of schizophrenia with predominant negative symptoms (phase III), as adjunctive therapy for major depressive disorder (phase II/III) and for the treatment of bipolar depression (phase II). This article summarizes the milestones in the development of cariprazine leading to this first approval for schizophrenia and manic or mixed episodes associated with bipolar I disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ginovart N, Kapur S. Role of dopamine D2 receptors for antipsychotic activity. Handb Exp Pharmacol. 2012;212:27–52.

    Article  CAS  PubMed  Google Scholar 

  2. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–73.

    CAS  PubMed  Google Scholar 

  3. Gross G, Drescher K. The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012;213:167–210.

    Article  CAS  PubMed  Google Scholar 

  4. Gyertyán I, Sághy K, Laszy J, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):529–39.

    Article  PubMed  Google Scholar 

  5. Kiss B, Laszlovszky I, Horváth A, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):515–28.

    Article  CAS  PubMed  Google Scholar 

  6. US FDA. FDA approves new drug to treat schizophrenia and bipolar disorder [media release]. 17 Sep 2015. http://www.fda.gov.

  7. US FDA. Vraylar™ (cariprazine): US prescribing information. 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed 29 Sep 2015.

  8. Forest Laboratories Inc. Gedeon Richter and Forest Laboratories announce collaboration agreement on atypical antipsychotic for schizophrenia, bipolar mania and other psychiatric disorders [media release]. 22 Nov 2004. http://www.frx.com.

  9. Gedeon Richter Ltd. License and collaboration agreement between Gedeon Richter Ltd. and Mitsubishi Pharma Corporation on development of an atypical antipsychotic [media release]. 11 May 2006. http://www.richer.hu.

  10. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–40.

    Article  CAS  PubMed  Google Scholar 

  11. Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011;218(3):579–87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226(1):91–100.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Gao Y, Peterson S, Masri B, et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2015;3(1):e00073.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925–35.

    Article  PubMed  Google Scholar 

  15. Slifstein M, Abi-Dargham A, D’Souza DC, et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-(+)-PHNO [abstract no. W128]. Neuropsychopharmacology. 2013;38(Suppl 2):S520–1.

    Google Scholar 

  16. Lee Y, Periclou A, Kapás M, et al. Pharmacokinetics of cariprazine in healthy subjects and patients with impaired hepatic function [abstract no. PI-101]. Clin Pharmacol Ther. 2014;95(Suppl 1):S51.

    Google Scholar 

  17. Pásztor Mészáros G, Kapás M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects [abstract no. P.3.c.047]. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S451–2.

  18. Nakamura T, Kubota T, Imada M. Pharmacokinetic characterization of cariprazine and its metabolites during 12 weeks of dosing and 12 weeks of follow-up [abstract no. 97]. In: 168th annual meeting of the American Psychiatric Association; 2015.

  19. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–7.

    Article  PubMed  Google Scholar 

  20. Lieberman JA, Cutler AJ, Wan S, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo-and active-controlled trial [abstract no. P.3.d.033]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S477–8.

    Article  Google Scholar 

  21. Cutler AJ, Durgam S, Lu K, et al. Trajectory of cariprazine treatment effects across schizophrenia symptoms: post hoc analysis of a randomized, double-blind, placebo and active-controlled trial [abstract]. Schizophr Bull. 2015;41(Suppl 1):S308.

    Google Scholar 

  22. Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S512–3.

    Article  Google Scholar 

  23. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63–75.

    Article  CAS  PubMed  Google Scholar 

  24. Calabrese JR, Keck PE, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–92.

    Article  PubMed  Google Scholar 

  25. Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double- blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296–302.

    Article  CAS  PubMed  Google Scholar 

  26. Debelle M, Németh G, Szalai E, et al. Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial [abstract no. P.3.d.053]. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S510.

    Article  Google Scholar 

  27. Earley W, Mergel V, Durgam S, et al. Cariprazine as adjunctive therapy in major depressive disorder: a double-blind, placebo-controlled study [abstract no. LP-02-009]. In: 29th International Congress of Collegium Internationale Neuro-Psychopharmacologicum; 2014.

  28. Calabrese JR, Durgam S, Lipschitz A, et al. Cariprazine monotherapy for the treatment of bipolar I depression: results of an 8-week, double-blind, placebo-controlled study [abstract no. T69]. Neuropsychopharmacology. 2014;39(S1):S335–6.

    Google Scholar 

  29. Durgam S, Lipschitz A, Guo H, et al. A double-blind, placebo-controlled study of cariprazine monotherapy for the treatment of bipolar I depression [abstract]. Bipolar Disord. 2015;17(Suppl 1):90–1.

    Google Scholar 

  30. Durgam S, Cutler AJ, Wang Y, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia [abstract no. M227 plus poster]. Schizophr Res. 2014;153(Suppl 1):S272.

    Article  Google Scholar 

  31. Ketter TA, Sachs GS, Lu K, et al. Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder [abstract no. P.2.d.024]. Eur Neuropsychopharmacol. 2013;23(Suppl 2):S377.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Paul L. McCormack

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Ethics declarations

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. P. L. McCormack is a salaried employee of Adis, Springer SBM.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCormack, P.L. Cariprazine: First Global Approval. Drugs 75, 2035–2043 (2015). https://doi.org/10.1007/s40265-015-0494-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0494-7

Keywords

Search

Navigation